Introduction
Antifungal drug resistance, especially to azoles, is prevalent in individuals with chronic mucocutaneous candidiasis (CMC), including those with primary immunodeficiencies (PIDDs) like autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), women with recurrent vulvovaginal candidiasis and AIDS patients. [1] [2] [3] [4] In cases of azole resistance, amphotericin B or the echinocandins are used and are often effective. 5 However, these are parenteral drugs and there is toxicity (amphotericin B) or emergence of resistance (echinocandins) associated with chronic use.
Azoles target fungal 14a-demethylase cytochrome P450 (CYP51), but can also affect human CYP51. 6 The development of a new class of antifungals that targets fungal CYP51 without significantly affecting the human homologue 6 shows promise for improved treatment options. One of these compounds, VT-1161, showed great preclinical promise in treating a wide range of mycoses, including fluconazole-susceptible and -resistant strains of Candida albicans in vulvovaginal candidiasis, dermatophytosis, mucormycosis and coccidioidomycosis, [7] [8] [9] [10] [11] and is currently in Phase 2 clinical trials for the treatment of vulvovaginal candidiasis and onychomycosis. Another associated compound, VT-1129, has shown great preclinical efficacy in treatment of cryptococcosis. 12 The compounds' efficacy against azole-resistant Candida strains, 7, 13 the low potential for drug-drug interactions 6 and their long half-lives 7, 8, 11 make them attractive options for patients with PIDDs that manifest with CMC. In this study, we examined whether VT-1129 and VT-1161 were effective in vitro and in vivo against fluconazole-susceptible and -resistant strains of Candida spp. that were collected from APECED patients with CMC.
Materials and methods

In vitro susceptibility
We tested the in vitro susceptibility of 31 mucosal Candida strains obtained from APECED patients to VT-1129, VT-1161 and nine licensed antifungal agents (fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B and flucytosine) using CLSI broth microdilution guidelines (M27-S4).
14 SC5314 was used as a quality control strain. VT-1161 and VT-1129 were dissolved in DMSO and diluted to a concentration range of 0.03-16 mg/L. The 24 h MICs at which 50% (MIC 50 ) and 90% (MIC 90 ) of strains were inhibited were determined once per strain.
Mice
We used age-and sex-matched Act1 #/# mice (also known as Ciks #/# , Traf3ip2 #/# mice), which lack IL-17 receptor signalling 15 and have heightened susceptibility to oral infection caused by C. albicans. 16 All experiments were conducted in accordance with the guidelines set forth by the Guide for the Care and Use of Laboratory Animals under a protocol approved by the NIAID Animal Care and Use Committee.
Candida strains and infection model
Twenty C. albicans, six Candida glabrata and one each of Candida nivariensis, Candida krusei, Candida utilis, Candida dubliniensis and Candida parapsilosis were isolated from APECED patients. For oropharyngeal candidiasis (OPC) experiments, the fluconazole-susceptible strain Y72 (MIC 0.5 mg/L) and the fluconazole-resistant strain Y37 (MIC 64 mg/L) were used. Sublingual infections and cfu determination were performed as reported previously. 17 
Antifungal drug administration
Fluconazole (25 mg/kg; LKT Laboratories, Inc.), VT-1161 (1, 5 or 20 mg/kg) or VT-1129 (20 mg/kg) was suspended in 0.5% carboxymethylcellulose (Sigma-Aldrich) and given to mice in four daily doses via oral gavage either without infection (drug levels) or starting 18 h post-infection (cfu assessment). As control, mice were given vehicle alone in the same treatment scheme ( Figure 1a ). One day after the fourth dose, tongues were collected for either fungal cfu or drug level determination, which was also performed in serum. VT-1161 and VT-1129 concentrations were determined using LC-MS/MS with electrospray ionization by OpAns LLC, as reported previously. 10 Viamet Pharmaceuticals, Inc. (Durham, NC, USA) supplied VT-1161 and VT-1129.
Statistical analysis
Mann-Whitney U-tests or unpaired t-tests were used, where appropriate, to assess statistical significance using GraphPad Prism 7 software. Data are presented as mean + SEM. A P value of ,0.05 was considered significant.
Results
VT-1161 and VT-1129 have significant in vitro activity against clinical C. albicans isolates obtained from APECED patients
To determine the prevalence of antifungal resistance in mucosal isolates obtained from our APECED patients, MICs of nine licensed antifungals, VT-1129 and VT-1161 were determined for 31 Candida strains (Table S1 , available as Supplementary data at JAC Online). Five out of 20 (25%) C. albicans strains exhibited fluconazole MICs above the CLSI breakpoint for susceptibility; 14 out of all 31 Candida strains (45%) had a fluconazole MIC 4 mg/L (MIC 50 4 mg/L; MIC 90 128 mg/L). Cross-resistance was seen infrequently between fluconazole and itraconazole (n " 3, all C. glabrata) and between fluconazole and posaconazole (n " 3, C. glabrata), but was not identified between fluconazole and voriconazole. No resistance to amphotericin B or the echinocandins was seen, while two isolates were resistant to flucytosine. Collectively, in agreement with other patient cohorts, 1 a substantial proportion of mucosal Candida strains recovered from APECED patients was not susceptible to fluconazole in vitro.
VT-1129 and VT-1161 showed significant in vitro activity against 27 (87%) and 30 (97%) of the 31 isolates tested, respectively. Specifically, the MIC 50 s of VT-1129 and VT-1161 were 0.06 and 0.03 mg/L, respectively, and the MIC 90 s of VT-1129 and VT-1161 were .16 and 0.5 mg/L, respectively (Table 1) . Among the 14 non-susceptible Candida strains with fluconazole MICs 4 mg/L, the MIC 50 s of VT-1129 and VT-1161 were 0.25 and 0.125 mg/L, respectively, while the MIC 90 of both drugs was 2 mg/L, with significant in vitro activity against C. glabrata strains. Consistent with a CYP51 inhibitor, 18 VT-1161 was fungistatic in vitro against the C. albicans ATCC 90028 strain (MIC ,0.03 mg/L) in a time-kill assay (data not shown). These data indicate that both VT-1129 and VT-1161 have in vitro activity against mucosally derived Candida isolates from CMC patients.
VT-1129 and VT-1161 accumulate in the mouse oral mucosa
To determine whether VT-1129 and VT-1161 distribute to the site of OPC, we administered the drugs via oral gavage to Act1 #/# mice for 4 days and determined the drug levels in the serum and tongue 1 day after the last dose. We used Act1 #/# mice, which lack IL-17 receptor signalling, as a representative model for human PIDDs that manifest with CMC. 19 All mice had detectable levels of both VT-1129 (n " 6) and VT-1161 (n " 6) in the serum and tongue. The drug levels for both VT-1129 and VT-1161 were significantly greater in the tongue (in lg/g) than the serum (in mg/L) (P , 0.001 for VT-1129 and P , 0.01 for VT-1161). Notably, VT-1161 had significantly greater levels than VT-1129 both in the tongue (mean, 42+6.3 versus 14+1.6 lg/g, respectively; P , 0.01) and in serum (9.7+0.9 versus 3.9+0.6 mg/L, respectively; P , 0.01). Importantly, the mean VT-1129 level in the tongue (in lg/g) was 233-fold greater than the MIC 50 value (in mg/L) for the 31 tested isolates (Table 1) , but not higher than the MIC 90 , and the mean VT-1161 levels in the tongue (in lg/g) were 1400-fold and 84-fold greater than the MIC 50 and MIC 90 values (in mg/L) for the 31 tested isolates, respectively (Table 1) . Therefore, oral administration of VT-1129 and VT-1161 results in substantial concentrations in mouse serum and, significantly more so, in the oral mucosa.
VT-1161 eliminates the in vivo growth of fluconazolesusceptible and -resistant C. albicans during OPC in mice (Figure 1a for schematic). One day after the final drug dose (day 5 post-infection), the tongue fungal load was determined. VT-1611 cleared Y72 from the mouse tongue, as no C. albicans colonies were recovered, while all mice given fluconazole treatment had detectable C. albicans in their tongues (Figure 1b) . We next determined whether VT-1161 is effective as treatment of OPC with the fluconazoleresistant C. albicans strain Y37 (MIC of VT-1161 " 0.06 mg/L; MIC of fluconazole " 64 mg/L). VT-1161 cleared the infection with the fluconazole-resistant C. albicans strain (Figure 1c) , while fluconazole only conferred a slight, but significant, decrease in fungal cfu in the tongue, relative to vehicle-treated mice. Lastly, we sought to determine whether lower doses of VT-1161 could still effectively treat OPC. Strikingly, administration of 5 mg/kg VT-1161 cleared C. albicans Y72 from the tongue, and even reducing the dose to 1 mg/kg significantly reduced fungal load, but did not completely clear the infection (Figure 1d) . Together, the results reveal a striking in vivo activity of VT-1161 in treating both fluconazole-susceptible and fluconazole-resistant C. albicans strains during OPC. #/# mice were infected with the Y72 C. albicans strain and treated with vehicle, 1 mg/kg VT-1161 or 5 mg/kg VT-1161 as in (a) and fungal load was determined at day 5 post-infection (d). Data were combined from two independent experiments with a total of five to seven mice per group. Data were analysed using Mann-Whitney U-tests or unpaired t-tests, where appropriate. An * or ** indicates that the groups differ at P , 0.05 or 0.01, respectively.
VT-1161 and oropharyngeal candidiasis JAC for treatment of OPC is attractive due to its superior protection against fluconazole-susceptible and fluconazole-resistant C. albicans isolates, but also due to its lack of cross-reactivity with human CYP51. 6 Moreover, VT-1161 has a favourable safety profile without significant side effects in human trials to date. Moreover, the drug's long half-life may allow for once-weekly administration for prophylaxis and/or treatment of CMC, as is currently being used in Phase 2b studies of vulvovaginal candidiasis (NCT02267382) and onychomycosis (NCT02267356).
Our study has limitations. Although we attempted to develop a model of OPC with two different mucosal C. glabrata strains in Act1 #/# mice, no infection could be established, consistent with the lower virulence of C. glabrata to cause mucosal disease in mice. 20 Moreover, future studies will be required to evaluate the efficacy of VT-1161 in larger numbers of mucosal Candida strains from CMC patients and to test the safety and efficacy of VT-1161 in the management of mucosal candidiasis in CMC patients. Break et al.
